Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Armata Pharmaceuticals Inc ARMP

Healthcare Biotechnology
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. Th Company is engaged in developing and advancing a pipeline of natural and synthetic phage candidates, including clinical... see more

Recent & Breaking News (NYSEAM:ARMP)

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2023 Results and Provides Corporate Update

PR Newswire March 21, 2024

Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva

PR Newswire March 4, 2024

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit

PR Newswire February 21, 2024

Armata Pharmaceuticals Announces Third Quarter 2023 Results and Provides Corporate Update

PR Newswire November 14, 2023

Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

PR Newswire October 30, 2023

Armata Pharmaceuticals Announces Presentation at Phage Futures: Global Digital Summit 2023

PR Newswire October 19, 2023

Armata Pharmaceuticals Announces First Patient Dosed in the Phase 2a Portion of the Phase 1b/2a 'diSArm' Study of AP-SA02 in Adults with Bacteremia Due to Staphylococcus aureus

PR Newswire September 26, 2023

Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

PR Newswire September 21, 2023

Armata Pharmaceuticals Announces Second Quarter 2023 Results and Provides Corporate Update

PR Newswire August 14, 2023

Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics

PR Newswire July 11, 2023

Armata Pharmaceuticals Announces Oral Presentation Detailing Results from the Phase 1b/2a SWARM-P.a. Clinical Trial at the 6th World Conference on Targeting Phage Therapy

PR Newswire May 31, 2023

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

PR Newswire May 11, 2023

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results and Provides Corporate Update

PR Newswire March 16, 2023

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a SWARM-P.a. Clinical Trial of Inhaled AP-PA02 in Patients with Cystic Fibrosis

PR Newswire March 6, 2023

Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC

PR Newswire January 10, 2023

Armata Pharmaceuticals Announces Completion of its Phase 1b/2a 'SWARM-P.a.' Study of Inhaled AP-PA02 in Cystic Fibrosis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection

PR Newswire December 22, 2022

Armata Pharmaceuticals to Participate in the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

PR Newswire November 28, 2022

Armata Pharmaceuticals Announces Third Quarter 2022 Results and Provides Corporate Update

PR Newswire November 9, 2022

Armata Pharmaceuticals Announces Second Quarter 2022 Results and Provides Corporate Update

PR Newswire August 11, 2022

Armata Pharmaceuticals Announces Clearance of IND for Prosthetic Joint Infections

PR Newswire August 1, 2022